u/Pure_Lynx_6424

Author argues HCW Biologics withheld a positive Akron Biotech distribution agreement to push a dilutive Schedule 14A proxy, crushing the price while insiders accumulate at low strikes. Core commercial assets HCW11-006 and HCW9302 were allegedly transferred to Beijing Trimmune for pennies, sheltered from US liquidation under Exhibit 10.40 Section 9.2.2, leaving public holders with the going-concern liabilities. A material weakness 8-K allegedly overstated EPS by $0.80-$2.19, and Proposal Two seeks a 2.5M-share insider option reserve that a >60% insider voting bloc will pass at the October 27 vote. Main risk is that the author's fraud allegations are unproven and the vote outcome is already priced in.